Psychedelic Drugs - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511240852

Publication Date:

November 11, 2024

Pages:

170

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Psychedelic Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Psychedelic Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Psychedelic Drugs by region & country, by Type, and by Application.
The Psychedelic Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Psychedelic Drugs.
麻豆原创 Segmentation
By Company
COMPASS Pathways PLC
Pfizer
Eli Lilly
GlaxoSmithKline
Cybin Inc
Field Trip Health
ATAI Life Sciences
NUMINUS WELLNESS
MindMed
HAVN Life Sciences
Seelos Therapeutics
Jannsen
Acadia Pharmaceuticals
Intellipharmaceutics
Revive Therapeutics
Mydecine Innovations Group
Red Light Holland
Braxia Scientific
Mind Cure Health
Entheon Biomedical
Segment by Type:
Psilocybin
LSD
MDMA
DMT
Ketamine
Others
Segment by Application
Depressive Disorders
Post-Traumatic Stress Disorders
Substance Abuse Disorders
Obsessive Compulsive Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Psychedelic Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Psychedelic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Psychedelic Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Psychedelic Drugs Product Introduction
1.2 Global Psychedelic Drugs 麻豆原创 Size Forecast
1.3 Psychedelic Drugs 麻豆原创 Trends & Drivers
1.3.1 Psychedelic Drugs Industry Trends
1.3.2 Psychedelic Drugs 麻豆原创 Drivers & Opportunity
1.3.3 Psychedelic Drugs 麻豆原创 Challenges
1.3.4 Psychedelic Drugs 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Psychedelic Drugs Players Revenue Ranking (2023)
2.2 Global Psychedelic Drugs Revenue by Company (2019-2024)
2.3 Key Companies Psychedelic Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies Psychedelic Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of Psychedelic Drugs
2.6 Psychedelic Drugs 麻豆原创 Competitive Analysis
2.6.1 Psychedelic Drugs 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Psychedelic Drugs Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Psilocybin
3.1.2 LSD
3.1.3 MDMA
3.1.4 DMT
3.1.5 Ketamine
3.1.6 Others
3.2 Global Psychedelic Drugs Sales Value by Type
3.2.1 Global Psychedelic Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Psychedelic Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Psychedelic Drugs Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Depressive Disorders
4.1.2 Post-Traumatic Stress Disorders
4.1.3 Substance Abuse Disorders
4.1.4 Obsessive Compulsive Disorders
4.1.5 Others
4.2 Global Psychedelic Drugs Sales Value by Application
4.2.1 Global Psychedelic Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Psychedelic Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Psychedelic Drugs Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Psychedelic Drugs Sales Value by Region
5.1.1 Global Psychedelic Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Psychedelic Drugs Sales Value by Region (2019-2024)
5.1.3 Global Psychedelic Drugs Sales Value by Region (2025-2030)
5.1.4 Global Psychedelic Drugs Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Psychedelic Drugs Sales Value, 2019-2030
5.2.2 North America Psychedelic Drugs Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Psychedelic Drugs Sales Value, 2019-2030
5.3.2 Europe Psychedelic Drugs Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Psychedelic Drugs Sales Value, 2019-2030
5.4.2 Asia Pacific Psychedelic Drugs Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Psychedelic Drugs Sales Value, 2019-2030
5.5.2 South America Psychedelic Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Psychedelic Drugs Sales Value, 2019-2030
5.6.2 Middle East & Africa Psychedelic Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Psychedelic Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Psychedelic Drugs Sales Value
6.3 United States
6.3.1 United States Psychedelic Drugs Sales Value, 2019-2030
6.3.2 United States Psychedelic Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Psychedelic Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Psychedelic Drugs Sales Value, 2019-2030
6.4.2 Europe Psychedelic Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Psychedelic Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Psychedelic Drugs Sales Value, 2019-2030
6.5.2 China Psychedelic Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Psychedelic Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Psychedelic Drugs Sales Value, 2019-2030
6.6.2 Japan Psychedelic Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Psychedelic Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Psychedelic Drugs Sales Value, 2019-2030
6.7.2 South Korea Psychedelic Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Psychedelic Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Psychedelic Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Psychedelic Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Psychedelic Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Psychedelic Drugs Sales Value, 2019-2030
6.9.2 India Psychedelic Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Psychedelic Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 COMPASS Pathways PLC
7.1.1 COMPASS Pathways PLC Profile
7.1.2 COMPASS Pathways PLC Main Business
7.1.3 COMPASS Pathways PLC Psychedelic Drugs Products, Services and Solutions
7.1.4 COMPASS Pathways PLC Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.1.5 COMPASS Pathways PLC Recent Developments
7.2 Pfizer
7.2.1 Pfizer Profile
7.2.2 Pfizer Main Business
7.2.3 Pfizer Psychedelic Drugs Products, Services and Solutions
7.2.4 Pfizer Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.2.5 Pfizer Recent Developments
7.3 Eli Lilly
7.3.1 Eli Lilly Profile
7.3.2 Eli Lilly Main Business
7.3.3 Eli Lilly Psychedelic Drugs Products, Services and Solutions
7.3.4 Eli Lilly Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.3.5 GlaxoSmithKline Recent Developments
7.4 GlaxoSmithKline
7.4.1 GlaxoSmithKline Profile
7.4.2 GlaxoSmithKline Main Business
7.4.3 GlaxoSmithKline Psychedelic Drugs Products, Services and Solutions
7.4.4 GlaxoSmithKline Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.4.5 GlaxoSmithKline Recent Developments
7.5 Cybin Inc
7.5.1 Cybin Inc Profile
7.5.2 Cybin Inc Main Business
7.5.3 Cybin Inc Psychedelic Drugs Products, Services and Solutions
7.5.4 Cybin Inc Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.5.5 Cybin Inc Recent Developments
7.6 Field Trip Health
7.6.1 Field Trip Health Profile
7.6.2 Field Trip Health Main Business
7.6.3 Field Trip Health Psychedelic Drugs Products, Services and Solutions
7.6.4 Field Trip Health Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.6.5 Field Trip Health Recent Developments
7.7 ATAI Life Sciences
7.7.1 ATAI Life Sciences Profile
7.7.2 ATAI Life Sciences Main Business
7.7.3 ATAI Life Sciences Psychedelic Drugs Products, Services and Solutions
7.7.4 ATAI Life Sciences Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.7.5 ATAI Life Sciences Recent Developments
7.8 NUMINUS WELLNESS
7.8.1 NUMINUS WELLNESS Profile
7.8.2 NUMINUS WELLNESS Main Business
7.8.3 NUMINUS WELLNESS Psychedelic Drugs Products, Services and Solutions
7.8.4 NUMINUS WELLNESS Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.8.5 NUMINUS WELLNESS Recent Developments
7.9 MindMed
7.9.1 MindMed Profile
7.9.2 MindMed Main Business
7.9.3 MindMed Psychedelic Drugs Products, Services and Solutions
7.9.4 MindMed Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.9.5 MindMed Recent Developments
7.10 HAVN Life Sciences
7.10.1 HAVN Life Sciences Profile
7.10.2 HAVN Life Sciences Main Business
7.10.3 HAVN Life Sciences Psychedelic Drugs Products, Services and Solutions
7.10.4 HAVN Life Sciences Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.10.5 HAVN Life Sciences Recent Developments
7.11 Seelos Therapeutics
7.11.1 Seelos Therapeutics Profile
7.11.2 Seelos Therapeutics Main Business
7.11.3 Seelos Therapeutics Psychedelic Drugs Products, Services and Solutions
7.11.4 Seelos Therapeutics Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.11.5 Seelos Therapeutics Recent Developments
7.12 Jannsen
7.12.1 Jannsen Profile
7.12.2 Jannsen Main Business
7.12.3 Jannsen Psychedelic Drugs Products, Services and Solutions
7.12.4 Jannsen Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.12.5 Jannsen Recent Developments
7.13 Acadia Pharmaceuticals
7.13.1 Acadia Pharmaceuticals Profile
7.13.2 Acadia Pharmaceuticals Main Business
7.13.3 Acadia Pharmaceuticals Psychedelic Drugs Products, Services and Solutions
7.13.4 Acadia Pharmaceuticals Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.13.5 Acadia Pharmaceuticals Recent Developments
7.14 Intellipharmaceutics
7.14.1 Intellipharmaceutics Profile
7.14.2 Intellipharmaceutics Main Business
7.14.3 Intellipharmaceutics Psychedelic Drugs Products, Services and Solutions
7.14.4 Intellipharmaceutics Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.14.5 Intellipharmaceutics Recent Developments
7.15 Revive Therapeutics
7.15.1 Revive Therapeutics Profile
7.15.2 Revive Therapeutics Main Business
7.15.3 Revive Therapeutics Psychedelic Drugs Products, Services and Solutions
7.15.4 Revive Therapeutics Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.15.5 Revive Therapeutics Recent Developments
7.16 Mydecine Innovations Group
7.16.1 Mydecine Innovations Group Profile
7.16.2 Mydecine Innovations Group Main Business
7.16.3 Mydecine Innovations Group Psychedelic Drugs Products, Services and Solutions
7.16.4 Mydecine Innovations Group Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.16.5 Mydecine Innovations Group Recent Developments
7.17 Red Light Holland
7.17.1 Red Light Holland Profile
7.17.2 Red Light Holland Main Business
7.17.3 Red Light Holland Psychedelic Drugs Products, Services and Solutions
7.17.4 Red Light Holland Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.17.5 Red Light Holland Recent Developments
7.18 Braxia Scientific
7.18.1 Braxia Scientific Profile
7.18.2 Braxia Scientific Main Business
7.18.3 Braxia Scientific Psychedelic Drugs Products, Services and Solutions
7.18.4 Braxia Scientific Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.18.5 Braxia Scientific Recent Developments
7.19 Mind Cure Health
7.19.1 Mind Cure Health Profile
7.19.2 Mind Cure Health Main Business
7.19.3 Mind Cure Health Psychedelic Drugs Products, Services and Solutions
7.19.4 Mind Cure Health Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.19.5 Mind Cure Health Recent Developments
7.20 Entheon Biomedical
7.20.1 Entheon Biomedical Profile
7.20.2 Entheon Biomedical Main Business
7.20.3 Entheon Biomedical Psychedelic Drugs Products, Services and Solutions
7.20.4 Entheon Biomedical Psychedelic Drugs Revenue (US$ Million) & (2019-2024)
7.20.5 Entheon Biomedical Recent Developments
8 Industry Chain Analysis
8.1 Psychedelic Drugs Industrial Chain
8.2 Psychedelic Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Psychedelic Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Psychedelic Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

COMPASS Pathways PLC
Pfizer
Eli Lilly
GlaxoSmithKline
Cybin Inc
Field Trip Health
ATAI Life Sciences
NUMINUS WELLNESS
MindMed
HAVN Life Sciences
Seelos Therapeutics
Jannsen
Acadia Pharmaceuticals
Intellipharmaceutics
Revive Therapeutics
Mydecine Innovations Group
Red Light Holland
Braxia Scientific
Mind Cure Health
Entheon Biomedical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.